CD274 and gastric cancer: The GEMSTONE-303 study demonstrated that, in patients with advanced GC or gastroesophageal junction adenocarcinoma and PD-L1 expression ≥5 %, the combination of sugemalimab and CAPOX significantly prolonged median PFS (7.6 months vs. 6.1 months) and OS (15.6 months vs. 12.6 months) compared to placebo.